Why did PHASQ fall 99.0% on 03 Jan 2026?

PHASQ’s collapse reflects extreme illiquidity, very low trading volume, residual effects from its Chapter 11 history and investor concern about clinical and restructuring outcomes; small orders can move the price dramatically.

What is Meyka AI’s grade for PHASQ and what does it mean?

Meyka AI rates PHASQ 63.07 out of 100 (Grade B, HOLD). The grade factors in sector comparison, financial metrics, forecasts and analyst signals; it signals mixed fundamentals and elevated risk.

Is there any realistic upside for PHASQ from this level?

Model projections show possible recovery scenarios — Meyka AI’s forecast base-case is $0.00050, implying large percentage upside versus $0.000001, but forecasts are model-based and not guarantees; outcomes depend on clinical and corporate events.

What are the biggest risks for PHASQ holders now?

Key risks are further dilution, clinical trial failure for lead candidates, regulatory setbacks, possible listing actions due to price and liquidity, and limited market depth causing volatile price swings.

US Stocks

PHASQ down 99.0% to $0.000001 on 03 Jan 2026 Market Hours: key concern

ByHuzaifa Zahoor January 3, 2026January 3, 2026

PHASQ stock, PhaseBio Pharmaceuticals, Inc., collapsed 99.0% on 03 Jan 2026 during market hours to trade at $0.000001 (PNK, United States, USD). The one-day fall left the stock at a fraction of its 52-week high of $0.0399 and pushed trading volume to 2,500 shares versus a 50-day average of 22,310. This move places PHASQ among today’s top losers, driven by extreme illiquidity and lingering restructuring and clinical risks. We unpack the trade data, key ratios, and what the drop means for holders and speculative traders.